CDKN2B

CDKN2B — Cyclin-Dependent Kinase Inhibitor 2B (p15/INK4b)

Introduction

```mermaid
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50
classDef protein fill:#0a1929,stroke:#2196f3
classDef disease fill:#2d0f0f,stroke:#e91e63
classDef pathway fill:#3e2200,stroke:#ff9800
classDef mechanism fill:#1a0a1f,stroke:#9c27b0
classDef therapeutic fill:#e0f2f1,stroke:#009688
CDKN2B["CDKN2B"] -->|"implicated_in"| neurodegeneration["neurodegeneration"]
CDKN2B["CDKN2B"] -->|"associated_with"| TGFBR1["TGFBR1"]
CDKN2B["CDKN2B"] -->|"associated_with"| CANCER["CANCER"]
CDKN2B["CDKN2B"] -->|"associated_with"| BMP2["BMP2"]
CDKN2B["CDKN2B"] -->|"associated_with"| TGFB2["TGFB2"]
CDKN2B["CDKN2B"] -->|"associated_with"| BMP7["BMP7"]
CDKN2B["CDKN2B"] -->|"associated_with"| Carcinoma["Carcinoma"]
CDKN2B["CDKN2B"] -->|"associated_with"| Ms["Ms"]
CDKN2B["CDKN2B"] -->|"associated_with"| Cancer["Cancer"]
CDKN2B["CDKN2B"] -->|"associated_with"| Tumor["Tumor"]
CDKN2B["CDKN2B"] -->|"therapeutic_target"| Cardiovascular["Cardiovascular"]
CDKN2B["CDKN2B"] -->|"therapeutic_target"| Aging["Aging"]
CDKN2B["CDKN2B"] -->|"associated_with"| Senescence["Senescence"]
CDKN2B["CDKN2B"] -->|"therapeutic_target"| Cardiac["Cardiac"]
CDKN2B["CDKN2B"] -->|"associated_with"| Stem_Cell["Stem Cell"]
CDKN2B["CDKN2B"] ==>|"promotes"| cardiomyocyte_degeneration["cardiomyocyte degeneration"]
CDKN2B["CDKN2B"] ==>|"activates"| CYCLIN_D1["CYCLIN D1"]
CDKN2B["CDKN2B"] -->|"co_discussed"| ENDOG["ENDOG"]
CDKN2B["CDKN2B"] ==>|"activa

...

CDKN2B — Cyclin-Dependent Kinase Inhibitor 2B (p15/INK4b)

Introduction

Cdkn2B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@retter1997]
<table> [@aguilar2014]
<tr><th colspan="2" style="background:#f0f0f0;">CDKN2B</th></tr> [@helgadottir2007]
<tr><td><b>Full Name</b></td><td>Cyclin-Dependent Kinase Inhibitor 2B</td></tr> [@northhurst2015]
<tr><td><b>Chromosome</b></td><td>9p21.3</td></tr> [@liu2021]
<tr><td><b>NCBI Gene ID</b></td><td>[1030](https://www.ncbi.nlm.nih.gov/gene/1030)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000147883</td></tr>
<tr><td><b>OMIM ID</b></td><td>600431</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P42772](https://www.uniprot.org/uniprot/P42772)</td></tr>
<tr><td><b>Protein Class</b></td><td>INK4 family (CDK inhibitor)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Cancer, Cardiovascular Disease, [Alzheimer's Disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>

Overview

CDKN2B (Cyclin-Dependent Kinase Inhibitor 2B), also known as p15/INK4b, is a key tumor suppressor gene located in the 9p21.3 chromosomal region. This gene encodes a cyclin-dependent kinase inhibitor that regulates cell cycle progression by inhibiting CDK4 and CDK6, thereby controlling the G1 to S phase transition. CDKN2B is a critical component of the INK4b-ARF-INK4a gene cluster, which encodes three essential tumor suppressors: p15, p14(ARF), and p16.

Function

CDK4/6 Inhibition

CDKN2B encodes p15, a member of the INK4 (Inhibitor of CDK4) family of proteins. p15 binds to and inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are required for G1 phase progression. When CDK4/6 are inhibited, they cannot phosphorylate the retinoblastoma protein (RB), maintaining RB in its active, growth-suppressive state and preventing S phase entry.

TGF-beta Signaling

CDKN2B expression is induced by transforming growth factor-beta (TGF-β), making it a key mediator of TGF-β's antiproliferative effects. TGF-β signaling activates SMAD transcription factors that directly upregulate CDKN2B expression, creating a tumor suppressive pathway that halts cell proliferation in response to growth inhibitory signals.

Cellular Senescence

p15 contributes to cellular senescence, an irreversible cell cycle arrest that serves as a barrier to tumorigenesis. By permanently halting cell division in response to oncogenic stress or DNA damage, p15 helps prevent the accumulation of mutations that could lead to cancer.

Epigenetic Regulation

The CDKN2B promoter is frequently silenced by [DNA methylation](/entities/dna-methylation) in cancers. Hypermethylation of the CDKN2B promoter leads to transcriptional repression, removing the CDK4/6 inhibition and allowing uncontrolled proliferation. This epigenetic silencing is observed in numerous cancers including leukemia, colorectal cancer, and gliomas.

Pathway Involvement

Cell Cycle Regulation (G1/S Checkpoint)

CDKN2B operates at the critical G1/S checkpoint of the cell cycle:

TGF-β or other antiproliferative signals induce CDKN2B expression

p15 protein binds to CDK4/6, inhibiting their kinase activity

RB remains hypophosphorylated and active

E2F transcription factors are sequestered

Cell cycle progression halts at G1 phase

INK4b-ARF-INK4a Locus

CDKN2B is part of a crucial tumor suppressor cluster on chromosome 9p21.3:

• CDKN2B (p15/INK4b): CDK4/6 inhibitor
• CDKN2A (p16/INK4a): CDK4/6 inhibitor (overlapping function)
• CDKN2A (p14/ARF): p53 stabilizer (different reading frame)

This cluster is one of the most frequently altered regions in human cancer.

TGF-β Signaling Pathway

As a TGF-β-inducible gene, CDKN2B mediates the cytostatic effects of TGF-β:

• SMAD2/3/4 complexes activate CDKN2B transcription
• p15 then reinforces growth arrest
• Loss of TGF-β signaling or CDKN2B enables escape from growth control

Disease Associations

Cancer

CDKN2B is frequently inactivated in human cancers:

• Acute Myeloid Leukemia (AML): CDKN2B deletion or methylation is common
• Colorectal Cancer: Epigenetic silencing occurs frequently
• Gliomas: Homozygous deletion or methylation
• Pancreatic Cancer: One of the most commonly deleted genes
• Melanoma: Often inactivated alongside CDKN2A

Cardiovascular Disease

Genome-wide association studies (GWAS) have identified CDKN2B variants as risk loci for:

• Atherosclerosis
• Coronary artery disease
• Myocardial infarction

The 9p21.3 locus containing CDKN2B is one of the strongest cardiovascular risk loci.

Alzheimer's Disease

Emerging evidence links CDKN2B to neurodegeneration:

• Cell cycle re-entry: Aberrant cell cycle activation in [neurons](/entities/neurons) is observed in AD brains, and CDKN2B may modulate this process
• [Tau](/proteins/tau) pathology: [CDK5](/proteins/cdk5)/p25 hyperactivity contributes to tau phosphorylation; CDKN2B may influence this pathway
• Neuronal senescence: p15-mediated senescence may contribute to age-related neuronal dysfunction
• Neuroinflammation: TGF-β signaling has complex roles in neuroinflammation

Myelodysplastic Syndromes

CDKN2B methylation and deletion are common in MDS, contributing to ineffective hematopoiesis and progression to AML.

Expression Pattern

CDKN2B exhibits tissue-specific expression:

• Ubiquitous: Low baseline expression in most tissues
• Induced expression: TGF-β responsive in many cell types
• High expression: Hematopoietic cells, endothelial cells
• Cell type specificity: Higher expression in slowly proliferating cells

Protein Interactions

CDKN2B interacts with key cell cycle proteins:

• CDK4: Direct binding and inhibition
• CDK6: Direct binding and inhibition
• Cyclin D1: Competes for CDK4/6 binding
• RB: Functional cooperation in growth arrest
• SMAD proteins: Transcriptional regulation

Therapeutic Implications

Cancer Therapy

CDKN2B restoration strategies are being explored:

• DNA demethylating agents: Can reactivate CDKN2B expression
• Histone deacetylase inhibitors: Epigenetic therapy approaches
• CDK4/6 inhibitors: Indirectly compensate for CDKN2B loss (e.g., palbociclib, ribociclib)

Cardiovascular Disease

Understanding CDKN2B's role in vascular biology may lead to:

• Risk stratification based on genetic variants
• Targeted therapies for atherosclerosis

Neurodegeneration

Research directions include:

• Modulating cell cycle regulators in neurons
• Understanding TGF-β neuroprotective signaling
• Senolytic approaches targeting p15-expressing cells

See Also

• [Cell Cycle Regulation](/mechanisms/cell-cycle)
• [TGF-beta Signaling Pathway](/mechanisms/tgf-beta-signaling-pathway)
• [Tumor Suppressor Genes](/genes/tumor-suppressor-genes)
• [CDKN2A (p16)](/genes/cdkn2a)
• [CDK4/6 Inhibitors](/mechanisms/cdk-inhibitors)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cellular Senescence](/mechanisms/cellular-senescence)

Background

The study of Cdkn2B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[KAMB et al., INK4b-ARF-INK4a locus in cancer (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7951326/)

[RETTER et al., TGF-beta induces CDKN2B (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9054490/)

[AGUILAR et al., CDKN2B methylation in leukemia (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24747824/)

[HELGADOTTIR et al., 9p21 locus and cardiovascular disease (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17478679/)

[NORTHHURST et al., Cell cycle re-entry in AD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25933503/)

[LIU et al., PRMT5 represses CDKN2B in colorectal cancer (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33664859/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CDKN2B discovered through SciDEX knowledge graph analysis: